The ongoing P-IV (ABLE-41) RWE study evaluates the effectiveness, overall experiences, patterns of use & safety of Adstiladrin in NMIBC patients aged ≥18yrs. that are receiving treatment in a clinical setting & have not previously received Adstiladrin in a clinical trial. The study will follow patients for 24mos.
The primary objective of the study is to evaluate if patients achieve CR at 3mos. and/or at any time within a year of their first installation. Additionally, the first patient was enrolled in the (ABLE-41) study in Sep 2023
Adstiladrin is an FDA-approved intravesical gene therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC with CIS with or without papillary tumors
Ref: Ferring Pharmaceutical | Image: Ferring Pharmaceutical
Related News:- Ferring Launches Rebyota for the Prevention of Recurrence of C. diff Infection in Adults in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
